WO2014075580A1 - Utilisation d'acide aurintricarboxylique dans la préparation d'un médicament ciblant le récepteur des chimiokines - Google Patents

Utilisation d'acide aurintricarboxylique dans la préparation d'un médicament ciblant le récepteur des chimiokines Download PDF

Info

Publication number
WO2014075580A1
WO2014075580A1 PCT/CN2013/086679 CN2013086679W WO2014075580A1 WO 2014075580 A1 WO2014075580 A1 WO 2014075580A1 CN 2013086679 W CN2013086679 W CN 2013086679W WO 2014075580 A1 WO2014075580 A1 WO 2014075580A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
ata
eae
day
mice
Prior art date
Application number
PCT/CN2013/086679
Other languages
English (en)
Chinese (zh)
Inventor
谢欣
张菲菲
魏巍
Original Assignee
中国科学院上海药物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院上海药物研究所 filed Critical 中国科学院上海药物研究所
Publication of WO2014075580A1 publication Critical patent/WO2014075580A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates to the field of biomedicine, and in particular to the use of aurintricarboxylic acid in the preparation of a medicament for targeting a chemokine receptor, and further relates to the preparation of a preventive and/or therapeutic autoimmune disease by aurintricarboxylic acid. Use of the drug. Background technique
  • MS Multiple sclerosis
  • EEE experimental autoimmune encephalomyelitis
  • DCs Dendritic cells
  • Immature DCs in peripheral tissues especially those in contact with the surrounding environment, like DCs in the skin and mucous membranes, will encounter them when they encounter antigens, and immature DCs will capture them and process them into small peptides.
  • Capacitive complex molecules present it to the cell surface.
  • signals from pathogens or inflammatory factors initiate the maturation process of DCs, further enhancing their antigen-presenting capacity.
  • the mature DC carries the antigen, moves out of the tissue, and reaches the secondary lymphatic organ.
  • DC stimulates the proliferation and differentiation of T cells by cell-to-cell contact and secretion of cytokines, thereby initiating an antigen-specific immune response.
  • chemokines can be broadly divided into two broad categories: chemokines that induce expression and chemokines that are constitutively expressed.
  • the constitutively expressed chemokine induces basic leukocyte migration and transport, forming a system of secondary lymphoid organs, and the chemokines that induce expression mainly recruit leukocytes to respond to physiological stress and stimulate the migration of inflammatory cells to inflammatory tissues.
  • Many studies have shown that the expression of multiple chemokines is up-regulated during EAE. After interfering with its function by specific antibodies to chemokines, it can well inhibit or alleviate the condition of EAE.
  • Chemokines are classified into four classes based on their very conserved cysteine residues at the N-terminus: CXC, due to an amino acid residue between its two adjacent cysteine residues; CC, two conserved Cysteine residue in close proximity; CX3C, two conserved cysteine The acid residues are separated by 3 amino acid residues; C, such chemokines have only one conserved cysteine residue at the N-terminus.
  • CXC and CC are two of the most important families of chemokines. Therefore, the present inventors took the receptors of these two types of chemokines as the main research object.
  • Chemokines function through chemokine receptors, one chemokine can be a ligand for multiple chemokine receptors, and one chemokine receptor can also have multiple chemokine ligands.
  • Chemokine receptors are a class of G-protein coupled receptors with seven transmembrane structures, and most are coupled to Gai , and their transduced signals are inhibited by pertussis toxin.
  • Chemokine receptors expressed in many cells, such as T cells, neutrophils, monocytes, monocyte-derived macrophages, natural killer cells, dendritic cells, eosinophils, and alkaloids
  • Cells involved in inflammation and immune response, such as neutrophils are also expressed in cells of the central nervous system such as microglia, astrocytes, neurons, and endothelial cells.
  • Different immune cells have different surface-specific high expression of chemokine receptors.
  • mature DCs express CCR7
  • Thl cells express CCR5 and CXCR3
  • Th17 cells express CCR6. Therefore, by interfering with the function of these chemokine receptors, the migration of the corresponding cells to the site of inflammation can be inhibited, thereby achieving the purpose of alleviating the condition of EAE.
  • ATA Aurintricarboxylic acid
  • CCR2 CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5, CXCR6.
  • ATA is an inhibitor of protein-nucleic acid interactions and is therefore capable of inhibiting many enzymes involved in DNA or RNA. Its ammonium salt is called an aluminum reagent and is used to detect aluminum in water, biological tissues and food.
  • ATA was found to exert anti-HIV activity by blocking the binding of the HIV coat protein gpl20 and CD4 molecules.
  • the inventors found that ATA can significantly alleviate the clinical symptoms and pathological changes of the mouse EAE model. Excessive activation of inflammatory cells and infiltration of tissues are common features of many autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, and the like.
  • ATA does not directly affect the differentiation of pathogenic Th1 or TW7 cells, but inhibits the migration and aggregation of antigen-presenting DC cells into the spleen, thereby reducing T cell activation and differentiation; ATA can also inhibit The migration of diseased T cells into the central nervous system, thereby alleviating the disease.
  • ATA a ATA or a pharmaceutical composition comprising ATA for the preparation of a medicament for targeting a chemokine receptor.
  • Another object of the present invention is to provide use of a ATA or a pharmaceutical composition containing ATA for the preparation of a medicament for preventing and/or treating an autoimmune disease.
  • the chemokine receptor comprises CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5, CXCR6.
  • the chemokine receptor is one or more selected from the group consisting of CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5 and CXCR6.
  • the spermidine tricarboxylic acid simultaneously targets three or more of the chemokine receptors.
  • the autoimmune diseases include multiple sclerosis, rheumatoid arthritis, erythema, and inflammatory bowel disease.
  • the present invention provides a method for preventing and/or treating an autoimmune disease, which comprises administering a therapeutically effective amount of ATA or a pharmaceutical composition containing ATA to a subject in need thereof.
  • the ATA-containing pharmaceutical composition comprises a therapeutically effective amount of aurin tricarboxylic acid and optionally a pharmaceutically acceptable carrier.
  • the present invention has the following advantages over existing chemokine inhibitors
  • ATA can simultaneously target multiple chemokines including CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5, CXCR6, etc., while inhibiting the migration of DC cells to secondary lymphoid organs and pathogenic T cells.
  • the migration to the central nervous system plays an inhibitory role in many aspects of the pathogenesis of autoimmune diseases, and may have a better therapeutic effect than drugs targeting a single chemokine.
  • Figure 1 shows the function of ATA to inhibit chemokine receptors. among them:
  • A is a diagram showing the molecular structural formula of ATA.
  • B is a graph showing the calcium flow response evoked by ATA inhibition chemokines.
  • HEK293 or CHO cell line stably expressing Gal6 and each receptor (CCR6, CCR7, CXCR4, S1P1, KOR or ⁇ 2 ⁇ ), after incubation with the dye fluo4-AM for 45 minutes, pre-incubated with ATA for 10 minutes, then with the corresponding ligand (30 nM) stimulation, calcium signal was recorded.
  • Data were from three independent experiments, three replicate wells per experiment, expressed as mean ⁇ standard error (mean ⁇ SEM).
  • C is a graph showing ATA inhibition of chemokine-induced cell chemotaxis.
  • Spleen cells isolated from female C57/B6 mice were stimulated with 10 ⁇ M ⁇ ⁇ LPS for 48 hours and then added to the upper chamber of the Transwell® transmembrane compartment sandwich system.
  • the upper and lower chambers were separated by microporous membranes; SDF Factors such as CCL19, CCL20 or SIP (both 30 nM) that induce cell migration are added to the lower chamber; different concentrations of ATA are added to the upper and lower chambers.
  • SDF Factors such as CCL19, CCL20 or SIP (both 30 nM) that induce cell migration are added to the lower chamber; different concentrations of ATA are added to the upper and lower chambers.
  • After 3 hours, cells migrating from the upper chamber to the lower chamber were counted by flow cytometry. Data were obtained from three independent experiments, three replicate wells per experiment, expressed as mean ⁇ standard error.
  • D is a graph showing endocytosis of ATA-inhibiting chemokine receptors. Expression of CXCR4, CCR6 or S1P1 receptors After the cells were stimulated with the corresponding ligands in the presence or absence of ATA, immunofluorescence staining of the receptors was performed to observe the localization.
  • the tailless arrow indicates that the receptor is located on the membrane, and the tail arrow refers to the endocytosis point formed by the receptor after endocytosis.
  • Figure 2 shows that ATA reduces the clinical signs and tissue damage of EAE. among them:
  • EAE was induced by immunizing female C57/B6 mice with MOG 35 _ 55 , once daily from the third day (A), day 12 (C) after immunization until the end of the experiment; or from the third day, administration By day 12 (B) ; the control group was given phosphate buffer and the clinical score was recorded daily. Data are expressed as mean ⁇ standard error (6 mice per group).
  • GI is a quantitative analysis of the total number of cell infiltration, demyelination area, and number of CD45+ cell infiltration in DF, and the data are expressed as mean ⁇ standard error.
  • Three mice were taken from each group, and 10 sections of each mouse spinal cord were analyzed for comparison. Compared with the control group, *** ⁇ 0.001 (Student's ?-test) o
  • Figure 3 shows that ATA inhibits in vivo but does not affect T cell differentiation in vitro. among them:
  • A On day 12 after EAE immunization, control group and ATA administration group (20 mg/kg/day, day 3 to day 12) CD4+ T cells, CD1 lc DC Thl (IFN- ⁇ ) in mouse spleen Flow cytometry analysis of cells and TW7 (IL-17 cell ratio; B: 12 days after EAE immunization, control group and ATA administration group (20 mg/kg/day, day 3 to day 12) murine splenocytes with MOG 35 - 55 weight supernatants were collected after 48 hours stimulation, measured by ELISA IL-17a IFN- ⁇ , IL -6 and TNF- ⁇ content; data are expressed as mean ⁇ standard error (each group 6 mice), compared with the control group, *p ⁇ 0.05 * p ⁇ 0.01, **p ⁇ 0.001 (Stittton's t-test); C and D: in the presence of differentiation factors and various concentrations of ATA From the spleen of 6-8 weeks old mice, the differentiation of naive CD4 + T cells
  • Figure 4 shows that ATA inhibits chemokine-mediated DC migration but does not affect other DC functions.
  • A DCs from the spleens of mice isolated on day 12 after EAE immunization were added to the Transwell® transmembrane compartment In the upper chamber of the culture system, the upper and lower chambers are separated by a membrane with micropores; 30 nM CCL19 is added to the lower chamber; ⁇ ⁇ is added to the upper and lower chambers. After 3 hours, cells migrating from the upper chamber to the lower chamber were counted by flow cytometry. Data were obtained from three independent experiments, three replicate wells per experiment, expressed as mean ⁇ standard error. Compared with the CCL19 untreated group, ### ⁇ 0.001 ; compared with the ATA untreated group, *** ⁇ 0.001 (Stittton's t-test).
  • CD4 + T cells and CD1 lc + DC were isolated from the spleen of ADA-treated mice on day 12 after EAE immunization, and CD4 + T cells were labeled with CFSE after MOG 35 _ 55 (25 ⁇ )
  • ATA 10 ⁇
  • 72 chambers were co-cultured, and the proliferation of CD4+ sputum cells by flow cytometry (D) or ELISA was used to measure IL-17a, IFN- ⁇ , IL-6 and TNF- in the supernatant.
  • FIG. 5 shows that ATA blocks the infiltration of inflammatory T cells into the central nervous system. among them:
  • mice Central nervous system infiltration in mice (ATA 20 mg/kg/day, day 3 to day 18) on day 18 after EAE immunization with 37-70% silica colloidal suspension (Percoll®) Cells, and the number of CD4+ T cells, Th1 (IFN-y) cells, and Th17 (IL-17 + ) cells were analyzed by flow cytometry. Data are expressed as mean ⁇ standard error (5 mice per group) compared to the control group, p ⁇ 0.05 (Stittton's t-test).
  • C57BL/6 female rats were purchased from Shanghai Experimental Animal Center (Shanghai, China) and raised in the SPF laboratory of the Experimental Animals Room of Shanghai Institute of Materia Medica. The light-dark 12-hour cycle was maintained, giving sufficient food and clean drinking water to The experiment was started at 8 weeks of age. All experiments were approved and introduced in accordance with the guidelines of the Animal Management and Use Committee of the Shanghai Institute of Materia Medica.
  • CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5, CXCR6, S1P1, DOR, KOR, 2AR and Gal6 plasmids were purchased from the Missouri S&T cDNA Resource Center.
  • Auchin tricarboxylic acid (ATA), lipopolysaccharide, Hochest33342, forskolin, GLP-1, U50488 and isoproterenol were purchased from Sigma-Aldricho anti-mouse CD3 (145-2C11) monoclonal antibody.
  • Anti-mouse CD28 (37.51) monoclonal antibodies and anti-mouse IFN- ⁇ (R4-6A2) monoclonal antibodies were purchased from BD Pharmingen.
  • Recombination MCP-l, TARC, RANTES, ⁇ -3 ⁇ , ⁇ -3 ⁇ , TECK, SDF-1, CXCL13 and ⁇ CXCL16 were purchased from PeproTech.
  • Recombinant murine IL-12, recombinant murine IL-6, recombinant human TGF- ⁇ , recombinant murine IL- ⁇ , recombinant murine IL-23 and recombinant murine TNF- ⁇ were purchased from R&D Systems.
  • the various cell lines stably expressing the receptor and God6 involved in the experiment were constructed in-house.
  • the specific steps are as follows: HEK293 or CHO cells are trypsinized, centrifuged, and 200 ⁇ M electroporation (ATP 200 g/L, MgCl 2 ⁇ 6H 2 0 120 g/L, KH 2 P0 4 12 g/L, NaHC0 3) 1.2 g/L), add the receptor plasmid and God6 plasmid 2 ⁇ ⁇ at a concentration of 100-200 million cells/200 ⁇ electroporation, mix well, and use Scientz-2C gene importer (Ningbo Xinzhi Biotechnology Co., Ltd.) Make an electric shock.
  • the cells are transferred to the culture plate or the culture dish to continue to culture the cells, and the cells can be used after 24 hours.
  • the calcium flow test was performed. After 24 hours in the culture dish, antibiotics were added for screening, and positive cloned cells were selected to establish a monoclonal cell line.
  • mice Female C57BL/6 mice were injected subcutaneously with 200 MOG35-55 (MEVGWYRSPFSRVVHLYRNGK, purchased from Jill Biochemistry) supplemented with complete Freund's adjuvant and 5 m ⁇ ml heat-killed Mycobacterium tuberculosis (H37Ra strain, purchased from Difco Laboratories). Day 0. Peripheral injection of pertussis toxin 200 ng per mouse on day 0 and day 2
  • mice were scored daily, and the scores were based on the "5-point scale" as follows: 0 points, no clinical symptoms; 1 point, tail sputum; 2 points, mild hind squats (unilateral or bilateral hind limb weakness, no Completely paralyzed); 3 points, paraplegia (complete paralysis of both hind limbs); 4 points, paraplegia and forelimb weakness or paralysis; 5 points, sudden death or death.
  • EAE administration group ATA (10-20 mg/kg) was administered intraperitoneally from the 3rd day or the 12th day after immunization until the end of the experiment; or from the 3rd day after immunization (administered ATA by intraperitoneal injection) (10-20 mg/kg) ) to day 12.
  • the solvent for dissolving ATA was phosphate buffered saline (PBS) containing 0.4% dimethyl sulfoxide (DMSO).
  • EAE control group A solvent control, i.e., a phosphate buffer containing 0.4% dimethyl sulfoxide, was administered by intraperitoneal injection from the 3rd day or the 12th day after immunization.
  • mice in the EAE administration group and the EAE control group in Example 1 were anesthetized, fixed by PBS perfusion and 4% paraformaldehyde perfusion.
  • the removed spinal tissue samples were fixed overnight in 4% paraformaldehyde.
  • inflammatory cell infiltration was analyzed by hematoxylin and eosin (H&E) staining, and demyelination of the spinal cord was analyzed by fast blue staining.
  • H&E hematoxylin and eosin
  • the spinal cord and brain tissue of the diseased mice of the EAE administration group and the EAE control group in Example 1 were ground on a 40 ⁇ filter, and the obtained cell suspension was centrifuged at 500 g for 10 minutes at 4° C., and 8 ml was used. Resuspend 37% Percoll® Reagent, carefully add to 4 ml of 70% Percoll® Reagent, and centrifuge at 25 °C 780 g for 25 minutes. Collect 37% to 70% Percoll® intermediate cells and perform flow assays.
  • Spleen cells of disease mice taken from the EAE administration group and the EAE control group in Example 1 or from Example 3 Surface staining of cells infiltrating into the mouse central nervous system. Cells were incubated with fluorescently labeled anti-mouse CD4, CD1 lc antibodies for 30 minutes at 4 °C.
  • CD4+ T cells Isolation of naive CD4+ T cells from spleens of 6-8 weeks old normal female C57BL/6 mice using magnetic beads (Dynal® Mouse CD4 Cell Negative Isolation kit; Invitrogen), and the isolated CD4+ T cells were added with anti-CD3 (2 g/ml).
  • mice from the EAE control group (12 days after immunization) or the EAE-administered group (ATA, 20 mg/k ⁇ day, day 3 administration) were sorted by MACS magnetic beads (Miltenyi Biotec). After CD1 lc + DC cells in the spleen on day 12, CD4 + T cells in the spleen of CFSE-labeled EAE-controlled mice (12 days after immunization) were mixed at a ratio of 3:1 in MOG.
  • CD4 + T cells and DC cells were isolated from EAE control mice (12 days after immunization) in co-culture system ⁇ (10 ⁇ ) was added, and after 72 hours of culture, the proliferation of CD4 + ⁇ cells was detected by flow cytometry.
  • the cytokines IFN- ⁇ , IL-17a, IL-6 and TNF- were detected by ELISA. The content of ⁇ (Dakewe, Shenzhen, China).
  • CDl lc + DCs from spleens of 8-10 week old normal C57BL/6 mice were incubated with ATA (0-30 ⁇ ) or camptothecin (0-30 ⁇ ) for 18 hours at 37 °C.
  • Cells were harvested for Annexin V/propidium iodide staining. Early apoptosis was positive for Annexin V, propidium iodide was negative, and late apoptosis was positive for Annexin V and propidium iodide. Detected by flow cytometry.
  • HEK293 cell lines stably constructed by various G-protein coupled receptors including CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5 and CXCR6) and Gal6 (constructed by the laboratory as described above) were inoculated In a 96-well plate, after 24 hours of incubation, incubate the cells with 2 ⁇ ⁇ 1 ⁇ 4- ⁇ dye for 45 minutes at 37 ° C, remove the dye, and add 50 ⁇ with different concentrations of ATA (0-100 ⁇ ) or 1% DMSO ( The negative control) of HBSS was incubated for 10 min at room temperature, and then stimulated with the corresponding ligands (SDF-1, CCL19, CCL20, SIP, etc.
  • G-protein coupled receptors including CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5 and CXCR6
  • Gal6 constructed by the laboratory as described above
  • the detector can automatically add 25 ⁇ agonist (final concentration 30 ⁇ ) to the reaction system, and simultaneously stimulate the intensity of dye fluorescence induced by intracellular calcium concentration change at 525 nm with 485 nm light. The change.
  • HEK293 cell lines stably expressing Myc-CXCR4, EGFP-CCR6 or HA-S1P1 were inoculated on coverslips and cultured overnight. Cells were pre-incubated with ATA (0-30 ⁇ ) for 10 minutes and then stimulated with the corresponding ligand (SDF-1, CCL20 or SIP) for 30 min at 30 nM.
  • the cells were fixed with 4% paraformaldehyde, 0.3% Triton X-100 was disrupted, and then incubated with anti-myc or HA-labeled antibody at 4 ° C overnight, and the corresponding Alexa Fluor 488 secondary antibody was incubated for 1 hour at room temperature, Hochest 33342 stained. After the nucleus, a photograph was taken with a fluorescence confocal microscope (Olympus FVlOi confocal microscope).
  • ATA inhibits the function of various chemokine receptors
  • Chemokine receptors are a class of G-protein coupled receptors (GPCRs) that play a very important role in cell migration and contribute to the pathogenesis of EAE.
  • GPCRs G-protein coupled receptors
  • Example 9 It can inhibit cell signal transduction and migration caused by various chemokines.
  • the inventors utilized stable expression of Gal6 and various GPCRs (including chemokine receptors including: CCR2, CCR4, CCR5, CCR6, CCR7, CCR9, CXCR4, CXCR5 or CXCR6; non-chemokine receptors) Including: S1P1, DOR, KOR, GLP-1R and ⁇ 2 ⁇ 0 cell lines detect the inhibitory effect of guanidine on GPCR-mediated calcium flux response.
  • Gal6 is a type of pan-host G protein, often associated with G protein-coupled receptors. Coupling, initiates a downstream calcium signaling pathway.
  • the results of Example 9 show that ATA dose-dependently inhibits most chemokine receptor-mediated calcium flux responses, except CCR2 only
  • Example 8 the inventors subsequently examined the effect of ATA on ligand activity of several different chemokines, such as CCL19/CCR7, CCL20/CCR6 or SDF-1/CXCR4, spleen cell migration.
  • the results of Example 8 show that ATA dose-dependently inhibits the migration of spleen cells induced by CCL19, CCL20 or SDF-1 with IC50 of 0.24, 3.36, 11.46 ⁇ , respectively (Fig. 1C, Table 1 below); S1P1 receptor It plays an important role in the migration of lymphocytes from secondary lymphoid organs, but ATA does not affect S1P1-mediated cell chemotaxis (Fig. 1C, Table 1 below).
  • Receptor endocytosis is a common phenomenon in which GPCRs are stimulated by their ligands.
  • the inventors also examined the effect of ATA on the endocytosis effects of CXCR4, CCR6 and S1P1 receptors after ligand stimulation.
  • Cells expressing CXCR4, CCR6 or S1P1 receptors were preincubated with ATA for 10 minutes and then stimulated with the corresponding ligands SDF-1, CCL20 or S1P for 30 minutes, followed by immunofluorescence staining of the receptor.
  • the results of Example 10 showed that the receptors were localized on the cell membrane without ligand stimulation, and the receptor was endocytosed into the cells after stimulation of the ligand (Fig.
  • Example 1 immunization with MOG 35 _ 55 8-9 week old female C57BL mice induced EAE / 6, from day 3 or day 12 by intraperitoneal injection of ATA (10 or 20 mg / kg) to the end of the experiment, Or dosing from day 3 to day 12.
  • the solvent control was PBS containing 0.4% DMSO.
  • the clinical score data for EAE are shown in Figures 2A-2C and Table 2 below.
  • ATA When administered only from day 3 to day 12, ATA was also able to reduce its severity at the onset and peak of EAE disease, but after 20 days, the disease score increased, indicating that drug removal resulted in The recurrence of the disease (Figure 2B). After the start of the disease (starting from the 12th day), 20 mg/kg ATA was still effective in reducing the severity of EAE (Fig. 2C, Table 2), indicating that the drug not only has a preventive effect, but also achieves the purpose of treating the disease.
  • Example 2 the inventors analyzed pathological sections of the spinal cord 21 days after immunization.
  • the results of the study of Example 2 showed that ATA administration significantly reduced leukocyte infiltration of the spinal cord compared to the control group (Fig. 2D and 2G); fast blue staining showed extensive demyelination of the white matter of the EAE mouse in the control group. Phenomenon, after deprivation of ATA, demyelination was significantly reduced ( Figures 2E and 2H); immunofluorescence staining of frozen sections showed that the number of CD45+ cells in the spinal cord of EAE mice was significantly reduced after ATA administration ( Figures 2F and 21). ).
  • Example 4 the inventors examined the proportion of each subpopulation of cells in the spleen of mice on the 12th day after EAE immunization by flow cytometry.
  • the ratio of the two major effector T cells Th1 and TW7 cells in CDl lc + DC and EAE of the ATA-administered mice was significantly lower than that of the control group ( FIG. 3A ).
  • This result is consistent with the administration group mouse splenocytes in vitro with MOG 35 - 55 weight stimulation, supernatant cytokines (including IFN-y, IL17, IL6 Wo ⁇ TNF- ⁇ ) have also significantly reduced (FIG. 3B ).
  • ATA reduced the proportion of these two cells in the spleen by directly affecting the differentiation of Th1 or TW7 cells.
  • naive CD4 + T cells were sorted from 6-8 week old female C57BL/6 mouse spleen cells by immunomagnetic beads, activated with anti-CD3 and anti-CD28 antibodies, and then added with different differentiation factors and Cells were induced to differentiate into Th1 or TW7 cells at various concentrations of ATA. Three days later, cells were collected for staining of intracellular IFN- ⁇ , IL-17a. Flow analysis revealed that ATA did not directly affect the in vitro differentiation of Th1 (Fig. 3C) or Thl7 (Fig. 3D).
  • Th1 or Thl7 in vivo The differentiation of Th1 or Thl7 in vivo is largely influenced by DC. Since ATA does not directly affect the differentiation of Th1 or TW7, the reduction of these cells in vivo is most likely due to the decrease in CD1 lc + DC (Fig. 3A). In Example 7, the inventors examined whether ATA promotes apoptosis of DC, thereby reducing the amount of DC in the spleen.
  • Figure 3E shows that the type I topoisomerase inhibitor camptothecin dose-dependently promotes apoptosis in DC, but ATA does not have this effect, indicating that ATA does not promote DC apoptosis.
  • DC then to secondary lymphoid organs Migration, and in these organs, present antigens to naive T cells, causing them to differentiate into Th1 or Thl7, thereby initiating an antigen-specific immune response.
  • ATA does not promote DC apoptosis, it is likely to inhibit DC migration to the spleen.
  • the inventors used chemotaxis experiments to study the effect of ATA on DC migration.
  • CCR7 is a major chemokine receptor that is highly expressed on mature DCs that mediates DC migration. The results showed that ATA (10 ⁇ ) was able to completely inhibit the chemotactic effect of the obtained DC isolated from the spleen of mice on day 12 after the induction of CCR7 ligand CCL19 (Fig. 4A).
  • Example 6 the inventors designed a DC-CD4+ T cell co-culture experiment in order to further verify whether ATA affects the antigen presentation of DCs to CD4 + T cells and the secretion of cytokines.
  • CD4 + T cells were isolated from control mice, labeled with CFSE, and co-cultured with CD1 lc + DC isolated from control EAE or ATA-administered EAE mice for 72 hours.
  • DCs from ATA-administered EAE mice had the same stimulation of CD4 + T cell proliferation (Fig. 4B) and their ability to secrete cytokines (Fig. 4C).
  • the inventors designed another experiment in which CD4 + T cells isolated from control EAE mice were co-cultured with CDl lc + DC, and ATA (10 ⁇ ) was added to the culture system, and flow was used 72 hours later.
  • the proliferation of CD4+ sputum cells (Fig. 4D) and their cytokine secretion were examined by ELISA and ELISA (Fig. 4 ⁇ -4 ⁇ ).
  • the results showed that co-culture of CD4 + T cells and CD1 lc + DC significantly enhanced the proliferation of CD4 + T cells and the production of cytokines.
  • MOG 35 — 55 stimuli can further enhance this effect.
  • ATA does not affect the proliferation of CD4 + T cells and the secretion of their cytokines in this system.
  • the protective effect of ATA on EAE is to inhibit the migration and aggregation of DC into the spleen, thereby reducing the activation and differentiation of T cells.
  • ATA blocks the infiltration of pathogenic lymphocytes into the central nervous system
  • ATA also showed a certain therapeutic effect after the onset of the disease (Fig. 2C). Therefore, the inventors further verified whether ATA affects the process of pathogenic T cells infiltrating into the central nervous system. Flow cytometry was used to detect CNS leukocyte infiltration on day 18 after immunization. After ATA administration, the number of CD4 + T cells and the two major pathogenic cells ThH and TW7 cells was significantly reduced (Fig. 5A). However, at the same time, the proportion of TW7 cells in the blood was found to be significantly increased in the ATA administration group as compared with the control group (Fig. 5B). This interesting phenomenon suggests that ATA may inhibit the infiltration of inflammatory T cells into the CNS, resulting in the accumulation of TW7 cells in the blood.
  • the choroid plexus forms part of the blood-brain barrier, and the passage of T cells through the choroid plexus into the central nervous system is a critical step in the initiation of EAE. It has been reported in the literature that CCL20/CCR6-mediated infiltration of Th1 cells into the CNS triggers the onset of EAE. CD45+ cells of CCR6 knockout mice cannot cross the blood-brain barrier and accumulate in the choroid plexus. Figures 5C and 5D show that there is more accumulation of CD45+ cells in the choroid plexus of EAE mice compared to the control group, which indicates that ATA also inhibits the infiltration of pathogenic T cells into the CNS. Thereby alleviating the condition of EAE. discuss
  • Chemokines are a class of cytokines associated with leukocyte migration and inflammatory responses that can be divided into two large families (CXC and CC) and two small families (C and CX3C) depending on their structural properties.
  • the chemokine receptor downstream signal is delivered by the heterotrimeric G protein.
  • G protein can regulate a variety of signaling pathways, including intracellular calcium, mitogen-activated protein kinases (MAPK), PLCP, PI3K, Ras and Rho GTPases. These transduction signals are thought to be responsible for the movement of cells and the transport of immune cells.
  • the immature DCs After the antigen enters the peripheral tissues, the immature DCs slowly mature under the induction of pathogens or inflammatory factors. Mature DCs carrying antigen migrate out of peripheral tissues to secondary lymphoid organs where they stimulate T cell proliferation and differentiation. During the maturation of DC, the type of chemokine receptors expressed on the surface changes. It is determined that the expression of the chemokine receptor CCR7, which is accumulated in the T cell-rich region, is gradually up-regulated by mature DCs carrying antigen. Recent studies have also shown that CXCR4 and CCR7-mediated signaling synergistically regulate DC migration to the spleen white pulp. Drugs that inhibit DC migration are used to treat autoimmune diseases.
  • CsA cyclosporin A
  • cytosporin A is a very important and effective immunosuppressive agent for the treatment of organ transplants, allergic disorders, autoimmune diseases and acute inflammation.
  • CsA mainly interferes with the expression of chemokine receptors by inhibiting the production of PGE 2 under LPS stimulation, and impairs the migration ability of DCs.
  • the inventors' data show that ATA non-specifically inhibits the function of chemokine receptors and that it is also best for inhibiting CCL19/CCR7-mediated DC chemotaxis. This suggests that inhibiting the homing of DCs to secondary lymphoid organs may be an effective method for treating autoimmune diseases.
  • lymphocytes into CNS are another key step in the development of EAE, a neurodegenerative disease, which is also regulated by chemokine receptors.
  • Leukocyte exudation from the blood to the extravascular is a multi-step process.
  • a key step in this cascade is the binding of chemokine receptors expressed on the surface of leukocytes in the circulation to chemokines on the surface of vascular endothelial cells, triggering intracellular signaling, leading to integrin activation, leukocyte arrest and extravasation .
  • TW7 cells expressing IL-17 are the most important pro-inflammatory T cells in EAE.
  • TW7 cells highly express the chemokine receptor CCR6, and its ligand CCL20 is highly expressed on choroid plexus cells of healthy and EAE mice.
  • Reboldi et al reported that the process of CCR6+ Thl7 cells entering the CNS through choroid plexus epithelial cells is very important for the initiation of EAE.
  • CCR6 knockdown can block the infiltration of TW7 cells and alleviate the condition of EAE.
  • the inventors have also demonstrated that ATA inhibits CCL20/CCR6-mediated chemotaxis of splenocytes and reduces the infiltration of inflammatory T cells into CNS.
  • ATA as a non-specific inhibitor of multiple chemokine receptors is responsible for its therapeutic effect on EAE. It is noteworthy that ATA has been reported to inhibit HIV entry by inhibiting the binding of CD4 to the viral envelope glycoprotein gpl20. It is well known that CCR5 and CXCR4 are co-receptors of HIV invasion. According to the inventor's data, ATA may also pass inhibition CCR5 and CXCR4 block HIV entry into CD4 + T cells.
  • the present invention discloses the activity of ATA to inhibit the function of chemokine receptors, and discloses the inhibition of ATA by
  • the process of CNS can achieve the purpose of treating EAE.
  • ATA inhibits chemokine receptor-mediated calcium flux response and cell migration. among them:
  • the inhibitory activity of ATA on various chemokine receptors and other GPCRs was examined by calcium flow and chemotaxis assays. The data was obtained from three independent experiments, three replicate wells per experiment, expressed as mean ⁇ standard error.

Abstract

La présente invention concerne une utilisation d'acide aurintricarboxylique (ATA) en tant qu'inhibiteur sélectif du récepteur des chimiokines. La présente invention concerne également une utilisation d'ATA dans la préparation d'un médicament pour la prévention et/ou le traitement des maladies auto-immunes comprenant la sclérose en plaques, la polyarthrite rhumatoïde, le lupus érythémateux et une affection abdominale inflammatoire.
PCT/CN2013/086679 2012-11-15 2013-11-07 Utilisation d'acide aurintricarboxylique dans la préparation d'un médicament ciblant le récepteur des chimiokines WO2014075580A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210461826.9 2012-11-15
CN201210461826.9A CN103800309A (zh) 2012-11-15 2012-11-15 金精三羧酸在制备靶向趋化因子受体的药物中的用途

Publications (1)

Publication Number Publication Date
WO2014075580A1 true WO2014075580A1 (fr) 2014-05-22

Family

ID=50698013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/086679 WO2014075580A1 (fr) 2012-11-15 2013-11-07 Utilisation d'acide aurintricarboxylique dans la préparation d'un médicament ciblant le récepteur des chimiokines

Country Status (2)

Country Link
CN (1) CN103800309A (fr)
WO (1) WO2014075580A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219849A1 (fr) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023072924A1 (fr) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023073082A1 (fr) 2021-10-28 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007270A (en) * 1975-11-18 1977-02-08 American Cyanamid Company Complement inhibitors
WO2010042728A1 (fr) * 2008-10-08 2010-04-15 Cornell University Modulateurs à petite molécule d'une absorption de prongf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631071A1 (fr) * 2008-05-09 2009-11-09 Tong-Jun Lin Inhibition des calpaines reduisant l'inflammation allergique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007270A (en) * 1975-11-18 1977-02-08 American Cyanamid Company Complement inhibitors
WO2010042728A1 (fr) * 2008-10-08 2010-04-15 Cornell University Modulateurs à petite molécule d'une absorption de prongf

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219849A1 (fr) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023072924A1 (fr) 2021-10-26 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
WO2023073082A1 (fr) 2021-10-28 2023-05-04 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6

Also Published As

Publication number Publication date
CN103800309A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
Wolf et al. Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation
Duan et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3+ regulatory T-cell responses in mice
Lande et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
Wills-Karp et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection
Riley et al. Regulating immunity to malaria
Besnard et al. IL‐33‐activated dendritic cells are critical for allergic airway inflammation
Chen et al. A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models
US11903997B2 (en) Modulators of syndecan-2 and uses thereof
Tong et al. Sinomenine suppresses collagen-induced arthritis by reciprocal modulation of regulatory T cells and Th17 cells in gut-associated lymphoid tissues
Nair et al. Immune polarization by hookworms: taking cues from T helper type 2, type 2 innate lymphoid cells and alternatively activated macrophages
KR20150039848A (ko) 면역-관련 및 염증성 질환의 치료
Wang et al. Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway
Mihara et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis
Matsuo et al. CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma
Zhang et al. IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response
Du et al. Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1 to promote eosinophilic airway inflammation
WO2014075580A1 (fr) Utilisation d'acide aurintricarboxylique dans la préparation d'un médicament ciblant le récepteur des chimiokines
Shamsdin et al. Alterations in Th17 and the respective cytokine levels in Helicobacter pylori‐induced stomach diseases
WO2013013490A1 (fr) Utilisation d'un médicament ciblant cyslt1 dans la préparation d'un médicament pour la prévention ou le traitement de maladies auto-immunes
Zhang et al. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity
Bachus et al. IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling
Chen et al. Topical application of interleukin-28A attenuates allergic conjunctivitis in an ovalbumin-induced mouse model
Dayton et al. Expression of IL-20 receptor subunit β is linked to EAE neuropathology and CNS neuroinflammation
Fukushima et al. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40
US10105418B2 (en) Oral administration of tocilizumab treatment of autoimmune disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13855495

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13855495

Country of ref document: EP

Kind code of ref document: A1